International Journal of Clinical Oncology

, Volume 10, Issue 3, pp 204–207 | Cite as

Amelanotic malignant melanoma of the esophagus: report of a patient with recurrence successfully treated with chemoendocrine therapy

  • Yoshihiro Suzuki
  • Norio Aoyama
  • Junji Minamide
  • Ken Takata
  • Takashi Ogata


We report a case of primary amelanotic malignant melanoma of the esophagus, an extremely rare disease. A 58-year-old man was diagnosed as having middle esophageal cancer with lymph node metastasis, which was classified as esophageal cancer, Stage III:T3N1M0, by International Union Against Cancer (UICC) criteria. Preoperative chemotherapy was performed, but the response assessment was no change (NC). The patient underwent a subtotal esophagectomy via right thoracotomy and laparotomy. Reconstruction was performed by pulling up the stomach via the retrosternal route; the site of anastomosis was the neck. Adjuvant chemotherapy consisted of five courses of dacarbazine (DITC), nimustine (ACNU), vincristine (VCR), and interferon-β. Eleven months after the surgery, computed tomography (CT) demonstrated recurrence in the upper mediastinum. The patient received chemoendocrine therapy, consisting of the first planned course of DITC, ACNU, and cisplatin (CDDP), given intravenously; and tamoxifen (TAM), given orally. Subsequently with a modified regimen of this therapy he attained a complete response (CR). In general, the prognosis of esophageal malignant melanoma is very poor. Although our patient had a recurrence, he is alive 4 years and 5 months after the surgery and 3 years and 6 months after the recurrence. The chemoendocrine therapy probably contributed to this outcome.

Key words

Amelanotic malignant melanoma Esophagus Tamoxifen 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Taniyama, K, Suzuki, H, Sakuramachi, S,  et al. 1990Amelanotic malignant melanoma of the esophagus: case report and review of the literatureJpn J Clin Oncol20286295PubMedGoogle Scholar
  2. 2.
    Watanabe, H, Yoshikawa, N, Suzuki, R,  et al. 1991Malignant amelanotic melanoma of the esophagusJpn Soc Gastroenterol26209212Google Scholar
  3. 3.
    Hamdy, FC, Smith, JHF, Kennedy, A,  et al. 1991Long survival after excision of a primary malignant melanoma of the oesophagusThorax46397398PubMedGoogle Scholar
  4. 4.
    Gadour, MOEH, Ayoola, EA 2000Primary malignant melanoma of the oesophagus: case report and reviewTrop Gastroenterol21185187PubMedGoogle Scholar
  5. 5.
    Lee, SH, Park, SH, Kim, HG,  et al. 1998Primary malignant melanoma of the esophagusYonsei Med J39468473PubMedGoogle Scholar
  6. 6.
    Naomoto, Y, Perdomo, JA, Kamikawa, Y,  et al. 1998Primary malignant melanoma of the esophagus: report of a case successfully treated with pre- and post-operative adjuvant hormone chemotherapyJpn J Clin Oncol28758761CrossRefPubMedGoogle Scholar
  7. 7.
    Archer, HA, Owen, WJ 2000Primary malignant melanoma of the esophagusDis Esophagus13320323CrossRefPubMedGoogle Scholar
  8. 8.
    Haga, Y, Iwanaga, Y, Matsumura, F,  et al. 1993Curatively resected primary malignant melanoma of the esophagus: report of a caseSurg Today23820824CrossRefPubMedGoogle Scholar
  9. 9.
    Del Prete, SAD, Maurer, LH, O’Donnell, J,  et al. 1984Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanomaCancer Treat Rep6814031405PubMedGoogle Scholar
  10. 10.
    Cocconi, G, Bella, M, Calabresi, F,  et al. 1992Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifenN Engl J Med327516523PubMedGoogle Scholar
  11. 11.
    Nesbit, RA, Woods, RL, Tattersall, MHN,  et al. 1979Tamoxifen in malignant melanomaN Engl J Med30112411242Google Scholar
  12. 12.
    McClay, EF, Mastrangelo, MJ, Sprandio, JD,  et al. 1989The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanomaCancer6312921295PubMedGoogle Scholar
  13. 13.
    Saida, T 2000Recent advancement in the diagnosis and treatment of malignant melanomaJpn J Dermatol11012671275Google Scholar
  14. 14.
    Gulino, A, Santoni, A, Screpanti, I,  et al. 1985Antitumoral antiestrogen stimulates natural killer activity in CH3 mouseJ Leukoc Biol38159162Google Scholar
  15. 15.
    Mandeville, R, Ghali, SS, Chausseau, JP 1984In vitro stimulation of human NK activity by an estrogen antagonistEur J Cancer Clin Oncol20983985CrossRefPubMedGoogle Scholar
  16. 16.
    Parmiani, G, Anichini, A, Fossati, G 1990Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?J Natl Cancer Inst82361370PubMedGoogle Scholar
  17. 17.
    Cohen, JHM, Danel, L, Cordier, G,  et al. 1983Sex steroid receptors in peripheral T cells: absence of androgen receptors and restriction of estrogen receptors to OKT8-positive cellsJ Immunol13127672771PubMedGoogle Scholar
  18. 18.
    Kono, K, Murakami, M, Sai, H,  et al. 1997Successful radiochemotherapy for malignant melanoma of the esophagusJpn J Cancer Clin43459465Google Scholar

Copyright information

© The Japan Society of Clinical Oncology 2005

Authors and Affiliations

  • Yoshihiro Suzuki
    • 1
  • Norio Aoyama
    • 1
  • Junji Minamide
    • 1
  • Ken Takata
    • 1
  • Takashi Ogata
    • 1
  1. 1.Department of Digestive SurgeryKanagawa Cancer CenterYokohamaJapan

Personalised recommendations